Scienture (NASDAQ: SCNX - Get Free Report) is anticipated to announce its results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Scienture Stock Down 3.1% Shares of NASDAQ: SCNX opened at $0.45 on Tuesday. The business's 50 day moving average is $0.46 and

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers

Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million

Scienture Holdings, Inc. (NASDAQ: SCNX - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totaling 3,504,653 shares, an increase of 46.2% from the December 31st total of 2,397,102 shares. Currently, 11.0% of the company's stock are sold short. Based on an average trading volume

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.

New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray.

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of REZENOPY®.

Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.

U.S. Losartan market totals $245M annually with 71M prescriptions  COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access platforms for branded medications, today announced a strategic collaboration to expand national access to Arbli™, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium.

Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript